American Journal of Gastroenterology. 111(1):30–50, JANUARY 2016

DOI: 10.1038/ajg.2015.322

,  

PMID: 26526079

Issn Print: 0002-9270

Publication Date: January 2016


Share this on facebook   Share this on Twitter   Share this on LinkedIn   Email this article  



Print

ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus

Nicholas Shaheen;Gary Falk;Prasad Iyer;Lauren Gerson;

+ Author Information


    loading  Checking for direct PDF access through Ovid

Abstract

Barrett’s esophagus (BE) is among the most common conditions encountered by the gastroenterologist. In this document, the American College of Gastroenterology updates its guidance for the best practices in caring for these patients. These guidelines continue to endorse screening of high-risk patients for BE; however, routine screening is limited to men with reflux symptoms and multiple other risk factors. Acknowledging recent data on the low risk of malignant progression in patients with nondysplastic BE, endoscopic surveillance intervals are attenuated in this population; patients with nondysplastic BE should undergo endoscopic surveillance no more frequently than every 3–5 years. Neither routine use of biomarker panels nor advanced endoscopic imaging techniques (beyond high-definition endoscopy) is recommended at this time. Endoscopic ablative therapy is recommended for patients with BE and high-grade dysplasia, as well as T1a esophageal adenocarcinoma. Based on recent level 1 evidence, endoscopic ablative therapy is also recommended for patients with BE and low-grade dysplasia, although endoscopic surveillance continues to be an acceptable alternative. Given the relatively common recurrence of BE after ablation, we suggest postablation endoscopic surveillance intervals. Although many of the recommendations provided are based on weak evidence or expert opinion, this document provides a pragmatic framework for the care of the patient with BE.

Related Topics

    Related Articles

        loading  Loading Related Articles